Published January 9, 2020 / All Stories
A quest to understand the rare and complex
It may seem like a simple question, but the answer can often be complex. Especially for scientists taking calculated risks in the lab to better understand complicated and sometimes rare diseases that affect people around the globe.
The questions of “why,” along with “how,” were central in an ongoing, multi-year collaboration between AbbVie and the Yale School of Medicine, a leader in immunology research.
This research-driven partnership sought to advance understanding of autoimmune and inflammatory disease, specifically the molecular, cellular and genetic underpinnings of these diseases. Since the partnership kickoff in 2014, it has focused on gastrointestinal, rheumatologic and dermatologic disorders, which can be tough to treat.
Today, scientists inside both AbbVie and Yale are deep in research projects that closely examine the mechanisms of these disorders with the goal of developing better, more targeted treatments.